A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
← catalyst calendarNCT06292780 · readout in 732 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
220estimated
Sites
21
Countries
Greece, South Korea, Spain +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-07 | actual | When the study began enrolling |
| Primary completion | 2028-08-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2035-02-20 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory Systemic Light Chain Amyloidosis
Intervention
- Drug: Linvoseltamab — also filed as REGN5458, Lynozyfic™
Primary outcomes
what the primary-completion date above is the date OFIncidence of dose-limiting toxicity (DLTs)
measured Up to 28 Days
Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)
measured Up to 3 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed